版本:
中国

BRIEF-BioMarin announces EMA validation for treatment of Batten Disease

Sept 15 BioMarin Pharmaceutical Inc

* BioMarin announces EMA validation of Brineura (cerliponase alfa) marketing authorization application for treatment of CLN2 disease, a form of batten disease

* Says decision from European Commission is anticipated by Q3 of 2017

* BioMarin Pharmaceutical Inc says validation of MAA confirms that submission is accepted and starts formal review process by EMA's committee for human medicinal products Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐